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However, to test the hypothesis that inflammation is the sole causal factor of MS-related structural and functional loss, experimental work studying long-term impact of early and complete elimination of inflammation is needed. This proves to be an extremely difficult task, as subclinical inflammation is often present during the pre-clinical disease stages. The apparently imperfect association between inflammation and neurodegeneration (and their clinical correlates) provides an intriguing food for thought, suggesting that additional pathognomonic factors may be involved. If this proves to be true, then no sooner will MS be conquered than we learn to control all of its multiple causative factors. journals.sagepub.com/home/msj Visit SAGE journals online journals.sagepub.com/ home/msj SAGE journals particular, they agree that inflammation is presumably a major driver of neurodegeneration in MS. They also agree that the currently available immunosuppressive treatments affect the neurodegenerative component of MS only very moderately, at best. Why is that so?
In MS, neurodegeneration occurs very early during the disease course and is intimately intertwined with the inflammatory process. Our clinical and magnetic resonance imaging (MRI) markers and endpoints are very crude compared to the overwhelming complexity of the biological disease process. For example, clinicians tend to equate inflammation with exacerbation frequency and MRI activity. Likewise, Expanded Disability Status Scale (EDSS) and even quantifiable brain atrophy are only coarse markers of neurodegeneration. For these reasons, it is not surprising that it is extremely difficult to prove a direct, let alone causal relationship between inflammation and neurodegeneration in MS.
Another reason why the relationship between neuroinflammation and neurodegeneration appears so complicated lies in our simplistic semantics. When we speak about "neuroinflammation," we refer to an incredibly complex biological process involving adaptive and innate immune mechanisms, B cells, T cells, antibodies, macrophages, dendritic cells, and microglia, all of which come in many different flavors. Moreover, the functional role and specific contribution of all these cells and mechanisms depend on the phase and type of MS (early or late, relapsing or progressive) and also on the localization of the inflammatory process in the periphery outside the central nervous system (CNS) or at different sites within the CNS, including meningeal and perivascular spaces, choroid plexus, cerebrospinal fluid (CSF), as well as parenchymal gray and white matter. Likewise, the term neurodegeneration cannot nearly capture the biological complexity of degenerative (irreversible) processes affecting axons, neurons, and different types of glia.
Therefore, for conclusively answering the question whether stopping inflammation can stop degeneration, we first need to better understand the biological nature of inflammation and degeneration in MS and how we can measure these processes and monitor their response to treatment.
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